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Abstract: The vascular endothelium, the largest “organ” in the body, synthesizes and releases 
a wide spectrum of vasoactive substances into the circulation. Endothelial dysfunction links 
hypertension and other cardiovascular (CV) risk factors that promote the development of 
atherosclerotic plaque, CV disease, and fatal and nonfatal CV events. Blood pressure (BP) 
reduction is the most effective way to reduce CV risk in patients with hypertension, but it 
is unknown whether endothelial dysfunction is a cause or consequence of hypertension. 
  Renin–angiotensin–aldosterone system blockers improve endothelial function and have favorable 
vascular, metabolic, cardiac, and renoprotective effects that are independent of BP reduction. 
Olmesartan effectively reduces BP and also has vasoprotective properties, including reductions 
in endothelial dysfunction and inflammation, prevention of microalbuminuria, and reversal of 
vascular remodeling. Large-scale, long-term studies are needed to confirm that olmesartan 
has vasoprotective effects that are independent of BP control and to determine whether these 
pleiotropic effects translate into improved CV disease outcomes.
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Introduction
The vascular endothelium is a thin layer of cells that line the interior surface of blood 
vessels separating circulating blood from layers of vascular smooth muscle cells 
(VSMC). Since the initial description of endothelium-derived relaxing factor (EDRF) 
by Furchgott and Zawadzki in 1980,1 the endothelium has been considered the   largest 
“organ” in the body. The endothelium synthesizes and releases a wide spectrum of 
vasoactive substances. This cellular monolayer both produces and responds to agents 
that regulate vascular tone, platelet aggregation, oxidative stress, inflammation, 
thrombogenicity, and VSMC proliferation.2 These include the vasodilators, such as 
nitric oxide (NO), prostacyclin, endothelium-derived hyperpolarizing factor, and 
carbon monoxide, and the vasoconstrictors, such as endothelin, superoxide anions 
(O2
−), prostanoids, and angiotensin II (Ang II). Both vasodilators and vasoconstrictors 
are tonically active, and the balance between those factors determines the normal or 
pathological state of the vasculature (Figure 1).
Endothelial dysfunction is the common link between cardiovascular (CV) risk 
factors, such as hypertension and diabetes, and CV diseases.3 For example, coronary 
vascular endothelial dysfunction independently predicts acute CV events in patients 
with and without atherosclerotic coronary artery disease.4 In this article, we discuss 
the relation between endothelial function, blood pressure (BP), and CV outcomes,  Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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with emphasis on the protective effects of the angiotensin 
receptor blocker (ARB) olmesartan medoxomil.
Endothelial function
Nitric oxide and oxidative stress
NO, originally described as EDRF,1 is a free radical, short-
lived, highly permeable gas. It is a potent vasodilator, inhibi-
tor of thrombocyte aggregation and leukocyte adhesion, and 
suppressor of the migration and proliferation of VSMC. 
NO is released by endothelial cells in response to activation 
of a variety of receptors, shear stress, changes in BP, and 
pulsatile stretch.5 It increases intracellular cyclic guanosine 
mono  phosphate concentrations by activating guanylate 
cyclase, leading to VSMC relaxation. NO is synthesized by 
NO synthase (NOS) from L-arginine, and its formation can 
be inhibited by false substrates for NOS such as NG-monom-
ethyl-arginine (L-NMMA).6,7 Thus, L-NMMA can be used 
as an experimental tool for assessing NO function in animal 
models of vascular disease.
NO plays an important role in BP regulation, thrombosis, 
and atherosclerosis. Experimentally induced hypertension 
promotes the release of NO, and decreases in BP suppress NO 
release, thus promoting vascular homeostasis. Inhibitors of 
NO production induce sustained hypertension when admin-
istered to animals, suggesting that the CV system is exposed 
to continuous tonic NO-dependent vasodilator tone.8
Endothelial dysfunction associated with systemic hyper-
tension is characterized by impaired NO bioactivity related 
to increased oxidative stress. Oxidative stress, a condition 
which occurs when the production of free radicals exceeds the 
body’s ability to neutralize and eliminate them, is believed to 
be a major cause of impaired NO bioactivity. Reactive oxygen 
species (ROS), including superoxide anions (O2
−), scavenge 
NO and reduce its bioavailability. ROS are generated from 
both nonenzymatic and enzymatic sources. Nicotinamide 
adenine dinucleotide phosphate(NAD(P)H) oxidase and 
cyclooxygenases are the major sources of O2
−.9 Thus, ROS, 
particularly O2
−, contribute to the vasoconstrictor effect of 
NO
EDHF
Prostacyclin
Carbon monoxide
Endothelin
Prostanoids
Angiotensin II
Superoxide anions  
Endothelial function
Figure 1 Agents that act continuously in the tone regulation of the vasculature.
Abbreviations: NO, nitric oxide; eDHF, endothelium-derived hyperpolarizing factor. Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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Ang II via their interaction with endothelium-derived NO. 
In addition to the scavenging effect of ROS, the reduced 
NO bioavailability observed in patients with hypertension 
compared with normotensive controls is due to a deficiency 
in NO synthesis (NOS activity).10
Some antihypertensive agents, such as the third genera-
tion vasodilating β blocker nebivolol, angiotensin-converting 
enzyme inhibitors (ACEIs), ARBs, and calcium channel 
blockers (CCBs), can improve endothelial function by 
increasing NO bioavailability or decreasing oxidative stress.9 
In addition, statins have a modest antihypertensive effect that 
has been attributed to potentiation of NO.11 Pharmacologi-
cal inhibition of 3-hydroxy-3-methylglutaryl coenzyme A 
reductase with statins stimulates endothelial NOS (eNOS), 
attenuating the expression of caveolin-1 and reducing the 
abundance of caveolae in endothelial cells. Caveolin plays a 
role in endothelial function, binding directly to and inhibiting 
eNOS, thus decreasing NO availability. Thus, attenuation of 
caveolin expression and related stimulation of eNOS may 
explain the BP-reducing effect of statins.
Clinical assessment  
of endothelial function
Several techniques are available for the assessment of 
endothelial function in humans (Table 1), but all of these 
have limited applicability in clinical practice. The “perfect” 
endothelial function test should be cheap, safe, noninvasive, 
reproducible, repeatable, and standardized among labora-
tories. However, none of the tests available fulfills these 
requirements.12 The gold standard for diagnosing endothelial 
dysfunction is assessment of the response to intraarterial 
infusion of acetylcholine.3 However, this test is rarely used 
in clinical practice because of its invasive nature.
Measurement of flow-mediated vasodilation of the bra-
chial artery by high-resolution ultrasonography is an accepted 
noninvasive method for assessment of endothelial function.13 
The diameter of the brachial artery is measured using high-
resolution ultrasound before and after occlusion of the artery 
for 5 minutes with sphygmomanometer cuff proximal to 
the brachial artery (Figure 2). When the cuff is released, the 
reactive hyperemia causes shear stress in the artery wall and 
release of NO. The amount of dilation is used as a marker 
of the endothelial function. Maximum vasodilation capac-
ity is induced using nitroglycerin for   comparison. Although 
noninvasive, this test is time-consuming and operator 
dependent.
Endothelial dysfunction contributes to arterial stiffness 
(reduction of elasticity), and estimation of arterial stiffness 
by pulse wave analysis has been used as marker of endothe-
lial dysfunction. Increased pulse wave velocity (PWV) 
and altered wave reflection are important determinants of 
increased systolic and pulse pressure and provide evidence 
of CV disease.14,15 With each ejection of blood from the left 
ventricle, a pressure (pulse) wave is generated and travels 
from the heart to the periphery at a finite speed that depends 
on the elastic properties of the conduit arteries. Increased 
arterial stiffness is correlated with elevated PWV . The pulse 
wave is reflected at any point of discontinuity in the arterial 
tree and returns to the aorta and left ventricle. The timing of 
the wave reflection depends on both the elastic properties 
and the length of the conduit arteries. Pulse wave analysis 
provides the augmentation index (AIx) that is a surrogate of 
wave reflection and is defined as augmented pressure (mag-
nitude of wave reflection) divided by pulse pressure.16
In younger persons (Figure 3, top panel), PWV is suf-
ficiently slow (approximately 5 m/s) that the reflected wave 
reaches the aortic valve after closure, leading to a higher 
diastolic BP and enhancing coronary perfusion by provid-
ing a “boosting” effect. In older persons, particularly if they 
are hypertensive, PWV is greatly increased (approximately 
20 m/s) due to central arterial stiffening. At this speed, the 
reflective wave reaches the aortic valve before closure, lead-
ing to a higher systolic BP, pulse pressure, and afterload and 
a lower diastolic BP (Figure 3, bottom panel). Coronary 
perfusion pressure is compromised in some cases secondary 
to low diastolic BP.
Endothelial dysfunction:  
from hypertension to CV disease
Endothelial dysfunction links hypertension with other 
CV risk factors that promote the development of athero-
sclerotic plaque, CV disease, and fatal and nonfatal CV 
events (Figure 4).17,18 Multiple studies have demonstrated 
Table 1 Methods for measuring endothelial function
Noninvasive
Ultrasound flow-mediated dilation
Flow-mediated magnetic resonance imaging
Pulse wave analysis
Pulse contour analysis
Laser doppler skin flowmetry
Pulse amplitude tonometry
Invasive
Cardiac catheterization
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impaired endothelial function in patients with   hypertension. 
  Endothelium-dependent vasodilation in response to acetyl-
choline infusion in the forearm and coronary circulations 
is impaired in patients with elevated BP.19–22 However, it 
is unknown whether endothelial dysfunction is a cause 
or consequence of hypertension. Normotensive offspring 
of   hypertensive parents exhibits impaired endothelium-
  dependent vasodilatation in response to acetylcholine.23 
Derangement of endothelial function in normotensive 
offspring of hypertensive parents is also demonstrated 
by decreased vasoconstriction in response to inhibition 
of NOS activity.24,25 Together, these findings support the 
Young
Old
Figure 3 Distensibility and pulse wave velocity (Pwv). Simple tubular models of the arterial system, connecting the heart (left) to the peripheral circulation (right). Top: normal 
distensibility and normal Pwv in a young subject. Bottom: decreased distensibility with increased Pwv in an old subject. Copyright © 2007. Reproduced with permission from 
O’Rourke MF, Hashimoto J. Mechanical factors in arterial aging: a clinical perspective. J Am Coll Cardiol. 2007;50(1):1–13.
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Figure 2 High-resolution ultrasound images showing the brachial artery before (left) and after (right) arterial occlusion. Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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  interpretation that endothelial dysfunction is an antecedent 
rather than a consequence of hypertension.
The renin–angiotensin–aldosterone system (RAAS), 
the main regulator of sodium and fluid balance in normal 
subjects and one of the major contributors to the patho-
genesis of hypertension, also plays an important role in the 
pathogenesis of endothelial dysfunction (Figure 5).26 Ang II 
increases oxidative stress by stimulating NAD(P)H oxidase, 
the main source of ROS in the vasculature, and accelerates 
senescence of endothelial progenitor cells (EPCs).27 EPCs, 
a rare population of cells that circulate in the blood with the 
ability to differentiate into endothelial cells, are a marker 
for vascular function and cumulative CV risk.28 Patients 
with coronary artery disease have lower circulating levels of 
EPCs and those with hypertension have accelerated senes-
cence of EPCs.29 This deficiency in EPC numbers/function 
may contribute to the development of endothelial function 
in these conditions.
Preclinical studies have demonstrated that activation of the 
Ang II type 1 (AT1) receptor contributes to the   development 
of atherosclerosis by mediating endothelial dysfunction. Com-
pared with wild type mice, apolipoprotein E knockout mice 
Elevated blood
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organ damage 
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event 
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Figure 4 Cascade of events that, if not blocked, will lead to death. Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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(ApoE−/−) have significantly greater O2
− formation, greater 
impairment in endothelium-dependent vasodilation, and more 
extensive atherosclerotic lesions development when fed a high 
cholesterol diet.30 In contrast, AT1 knockout mice (AT1−/−) 
have lower oxidative stress, reduced endothelial dysfunction, 
and less atherosclerotic plaque formation than wild type mice 
independently of BP and plasma cholesterol levels. Offspring 
of ApoE × AT1−/− matings has significantly lower O2
− and BP 
levels than ApoE−/− mice and do not develop atherosclerosis. 
These findings support the functional significance of Ang II 
in the generation of oxidative stress and atherosclerosis in 
this model.
RAAS blockers improve endothelial function and have 
favorable vascular, metabolic, cardiac, and renoprotec-
tive effects. ARBs reduce BP by selectively blocking the 
  binding of Ang II to the AT1 receptors in VSMC and other 
cell types.31 ARBs also reduce CV morbidity and mortality 
in patients with hypertension, left ventricular hypertrophy, 
diabetes, renal disease, and congestive heart failure.32–34 
Olmesartan medoxomil is a long-acting ARB approved 
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Figure 5 Mechanisms of action of angiotensin receptor blockers (ARBs).
Abbreviations: ANG I, angiotensin I; ANG II, angiotensin II; AT1, angiotensin II type 1 receptor; AT2, angiotensin II type 2 receptor; PAI-1, plasminogen activator 
inhibitor-1; NO, nitric oxide; PGF2, prostaglandin growth factor 2. Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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for the treatment of mild to severe hypertension that has 
  vasoprotective properties.
Olmesartan
Pharmacology
Olmesartan medoxomil is an inactive prodrug that is rapidly 
and completely bioactivated by ester hydrolysis in the gut 
wall to the pharmacologically active compound olmesartan. 
Its peak plasma concentrations are achieved between 1 and 
3 hours with an elimination half-life of 12–18 hours.35,36 
The absolute bioavailability of olmesartan medoxomil after 
oral administration is 26%–28.6%, and the steady-state 
plasma concentrations are reached within the first few days. 
  Accumulation is not noted on long-term dosing. Olmesartan 
is excreted unchanged in the urine (35%–50%) and in the bile. 
Olmesartan has minimal or no inhibitory activity on human 
cytochrome P450.35,36 A unique mechanism of binding to the 
AT1 receptor appears to contribute to the sustained duration of 
AT1 receptor blockade seen with olmesartan.37,38 This involves 
the “double chain domain”, whereby olmesartan binds to the 
receptor at two sites, a −OH group and an α-COOH group, 
whereas other ARBs bind only at the −OH group. Whether 
the more sustained inhibition of the pressor effects of infused 
angiotensin seen with olmesartan compared with other ARBs 
is secondary to the “double chain domain” is unknown.
Protective effects of olmesartan
Blood pressure
Olmesartan reduces BP rapidly and effectively in   hypertensive 
patients. An analysis of seven randomized, double-blind, 
  placebo- controlled, parallel group studies compared the 
safety (n = 2,540) and efficacy (n = 2,145) of olmesartan 
monotherapy with placebo in patients with essential hyperten-
sion (sitting diastolic BP $100 mm Hg and #115 mm Hg).39 
Olmesartan produced dose-dependent reductions in both dia-
stolic and systolic BP within 1 week of initiating treatment, 
and the response was nearly maximal at 2 weeks. There was 
no difference in efficacy between younger (,65 years) and 
older (.65 years) patients.
Olmesartan reduces BP more effectively than other ARBs 
when administered at traditionally recommended starting 
doses.40 A 588 patient, multicenter, randomized, double-blind 
trial compared once-a-day therapy with the recommended 
starting doses of olmesartan (20 mg), losartan (50 mg), val-
sartan (80 mg), and irbesartan (150 mg) in patients with high 
BP (cuff diastolic BP $100 mm Hg and #115 mm Hg, and a 
mean daytime diastolic BP $90 mm Hg and #120 mm Hg). 
A significantly greater reduction in sitting cuff diastolic BP 
at trough was demonstrated with olmesartan (11.5 mm Hg) 
compared with losartan, valsartan, and irbesartan (8.2, 7.9, and 
9.9 mm Hg, respectively, P , 0.005 olmesartan vs losartan; 
P , 0.05 olmesartan vs valsartan and irbesartan).41 Reductions 
in cuff systolic BP with the 4 ARBs had the same numerical 
trend, although differences between treatments were not sta-
tistically significant due to variability in the data. The reduction 
in mean 24-hour diastolic BP with olmesartan (8.5 mm Hg) 
was significantly greater than reductions with losartan and 
valsartan (6.2 and 5.6 mm Hg, respectively, P , 0.05) and 
showed a trend toward significance when compared with 
irbesartan (7.4 mm Hg; P = 0.087) (Figure 6). The reduction in 
mean 24-hour systolic BP with olmesartan (12.5 mm Hg) was 
significantly greater than those with losartan and valsartan (9.0 
and 8.1 mm Hg, respectively) and equivalent to the reduction 
with irbesartan (11.3 mm Hg). All drugs were well tolerated.
The differences in BP reduction achieved with olmesar-
tan compared with losartan and valsartan are attenuated 
when doses of the other ARBs are increased. In a 12-week, 
  randomized, double-blind, forced-titration study, 723 
hypertensive patients were assigned to receive olmesartan 
20 mg, losartan 50 mg, valsartan 80 mg, or placebo, all 
once   daily.42 Doses were titrated to 40, 100, and 160 mg 
once daily for olmesartan, losartan, and valsartan, respec-
tively, after 4 weeks of treatment. At week 8, doses were 
titrated to 50 mg twice daily for losartan and 320 mg once 
daily for   valsartan. Olmesartan remained at 40 mg once 
daily. Compared with placebo, all 3 medications signifi-
cantly reduced mean seated diastolic BP from baseline. 
At week 8, patients receiving olmesartan 40 mg once 
daily had significantly greater reductions in mean seated 
diastolic BP than those receiving losartan (−15.2/−12.9 
vs−10.9/−9.4 mm Hg, respectively, P , 0.001). There 
was no significant difference compared with valsartan. 
A significantly greater percentage of patients achieved 
BP goals (,140/90 mm Hg) with olmesartan compared 
with losartan and valsartan (39.7%, 19.8%, and 29.0%, 
respectively, P , 0.001 vs losartan and P = 0.031 vs val-
sartan). Olmesartan did not reduce mean seated systolic 
BP significantly compared with valsartan.
Microalbuminuria
Microalbuminuria is an early sign of glomerular endothelial 
dysfunction and is associated with progressive glomerulo-
sclerosis, renal function loss, and development of overt pro-
teinuria. Microalbuminuria is also associated with increased 
CV morbidity and mortality in both diabetic and nondiabetic 
subjects.43–47 Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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The Randomized Olmesartan and Diabetes Microal-
buminuria Prevention (ROADMAP) study,48 conducted in 
Europe, included 4,449 men and women. Participants had 
type 2 diabetes, normal kidney function, and at least one 
additional CV risk factor, including hypertension, but without 
microalbuminuria.49 They were randomly assigned to receive 
olmesartan 40 mg daily (n = 2,232) or placebo (n = 2,215), in 
addition to other antihypertensive medications (except ACEIs 
or ARBs) during the study in order to reach the target BP 
of ,130/80 mm Hg. Primary end point was time to onset of 
microalbuminuria, and secondary end points included renal 
and CV events. The mean baseline BP was 136/81 mm Hg. 
After 48 months, nearly 80% and 71% of patients in the 
olmesartan and placebo groups, respectively, reached target 
BP (,130/80 mm Hg). Patients in the olmesartan group were 
23% less likely than those in the placebo group to develop 
microalbuminuria at 48 months (8.2% vs 9.8%, hazard ratio 
0.77; 95% confidence interval: 0.63–0.94, P = 0.01). Overall, 
CV morbidity and mortality were similar (3.6% vs 4.1% in 
olmesartan vs placebo), but CV deaths occurred more fre-
quently in the olmesartan group (n = 15) than in the placebo 
group (n = 3, P = 0.01). The increased risk of CV mortality 
with olmesartan relative to placebo was attributed by the 
authors to possible hypotensive episodes in subjects with 
preexisting CV disease.
Inflammation, vascular remodeling,  
and endothelial function
Olmesartan has vasoprotective and anti-inflammatory 
effects that are unrelated to BP reduction. In the EUropean 
Trial on Olmesartan and Pravastatin in Inflammation and 
  Atherosclerosis (EUTOPIA) study, investigators com-
pared the anti-inflammatory effects of olmesartan alone 
and combined with pravastatin to placebo in patients with 
essential hypertension (sitting diastolic BP $95 mm Hg 
and #100 mm Hg) and microinflammation. Microinflam-
mation was defined as high-sensitivity C-reactive protein 
(CRP) $3 mg/L, and   detectable serum interleukin-6 (IL-6) 
and   intercellular   adhesion molecule-1.50 Patients were 
randomized to   olmesartan medoxomil 20 mg/d or placebo 
for 12 weeks. Hydrochlorothiazide 12.5–25 mg/d was 
added if diastolic BP $90 mm Hg. All patients received 
pravastatin 20 mg/d after 6 weeks of double-blind treat-
ment for the remainder of the study. Olmesartan treatment 
significantly reduced serum levels of high-sensitivity CRP, 
high-sensitivity tumor necrosis factor-α (TNF-α), IL-6, and 
monocyte chemotactic protein-1 compared with placebo 
independently of BP reduction. Treatment with pravastatin 
alone did not significantly alter inflammation markers. This 
study demonstrated that olmesartan significantly reduces 
biochemical markers of inflammation by as early as 6 weeks 
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of treatment,   resulting in possible additional CV benefits 
independent of BP reduction.
Olmesartan has a remedial effect on the remodeling 
of resistance vessels that result from hypertension-related 
target organ damage. The Vascular Improvement with 
Olmesartan medoxomil Study (VIOS) tested the hypothesis 
that, independent of BP control, suppression of the RAAS 
with olmesartan reverses abnormal remodeling of resistance 
vessels and has favorable effects on central hemodynamics 
compared with suppression of sympathetic drive with the 
β blocker atenolol.51 Nondiabetic patients (n = 100) with 
stage 1 hypertension were randomized to either olmesartan 
20 mg/d or atenolol 50 mg/d.52 The doses of olmesartan and 
atenolol were increased to 40 mg and 100 mg, respectively, 
with subsequent addition of other agents (hydrochlorothi-
azide, amlodipine, or hydralazine) if BP .140/90 mm Hg. 
Subcutaneous gluteal resistance arteries were examined on a 
pressurized myograph to evaluate vascular structure at base-
line and after 1 year of treatment. Before starting treatment, 
the wall width, media cross sectional area, and wall-to-lumen 
(W/L) ratio of resistance arteries were all significantly higher 
in patients with hypertension than in normotensive control 
subjects. In the presence of BP reduction to near normal levels 
in both groups, olmesartan (n = 27), but not atenolol (n = 22), 
significantly reduced all arteriolar dimensions. The mean W/L 
ratio in patients who received olmesartan was similar to that 
in normotensive controls. Further, AIx, a marker of vascular 
stiffness and endothelial function discussed previously, fell 
significantly with olmesartan, but remained unchanged with 
atenolol. Central aortic pressure decreased significantly in 
both groups without differences between groups.
Endothelial function has been shown to improve with olm-
esartan treatment independent of BP reduction. A prospective 
study assessed endothelium-dependent coronary dilation in 
26 untreated hypertensive patients.53 Changes of corrected 
myocardial blood flow (∆MBF) and coronary vascular resis-
tance (∆CVR) from rest to cold pressor were measured by 
using 15O-water and positron emission tomography before 
and after 12 weeks of treatment. Patients initially received 
olmesartan 20 mg or amlodipine 5 mg daily. After 1 month, 
doses were doubled if BP was .140/90 mm Hg, or halved if 
systolic BP ,110 mm Hg to olmesartan 40 mg or 10 mg or 
amlodipine 10 mg or 2.5 mg, respectively. Blood   biomarkers, 
including lipids, glucose, insulin, high-  sensitivity CRP, IL-6, 
TNF-α, and superoxide dismutase (SOD), were also mea-
sured. Mean dose was olmesartan 27.7 mg and amlodipine 
5.6 mg at the end of 12 weeks. ∆MBF tended to be greater, 
and ∆CVR was significantly decreased in the olmesartan 
group, but did not change in patients treated with amlodipine. 
Serum SOD activity tended to increase with olmesartan, but 
not with amlodipine. The authors concluded that olmesartan, 
but not amlodipine, improved endothelium-dependent coro-
nary function, and that these beneficial effects of olmesartan 
on coronary vasomotion might be mediated via an antioxidant 
property of the ARB.
Cv outcomes
Olmesartan has been shown to reduce the volume of athero-
sclerotic plaque in patients with hypertension independent of 
BP reduction. In the Multicenter Olmesartan atherosclerosis 
Regression Evaluation (MORE) study, carotid intima media 
thickness (IMT) and plaque volume were evaluated in 165 
hypertensive patients (systolic/diastolic BP 140–180/90–
105 mm Hg) with carotid artery disease and increased CV 
risk.54 Carotid artery disease was defined as IMT 0.8–1.6 mm 
and at least one plaque (volume 4–500 µL) in the common 
carotid artery or the carotid bulb. Patients were random-
ized to double-blind treatment with either olmesartan 
20 mg/d or atenolol 50 mg/d. Patients with uncontrolled BP 
(.140/90 mm Hg) after 4 weeks of treatment were titrated to 
olmesartan 40 mg or atenolol 100 mg once daily. Hydrochlo-
rothiazide 12.5 mg with up-titration to 25 mg after another 4 
and 8 weeks was added, if BP remained uncontrolled. After 
2 years, although both treatments reduced IMT similarly, 
preferential decreases in volume of larger plaques ($33.7 µL) 
were seen with olmesartan compared with atenolol (−11.5 vs 
+0.6 µL, P = 0.023). There were more men (73% vs 50%), 
current smokers (38% vs 31%), and patients with history of 
CV disease (14% vs 9%) in the atenolol than in the olmesartan 
group. The reductions in large plaques occurred despite simi-
lar reductions in BP, suggesting an antiatherosclerotic action 
of olmesartan that is independent of its BP lowering effect.
More recently, the results of the Impact of OLmesarten 
on progression of coronary atherosclerosis, evaluation by 
  IntraVascular UltraSound (OLIVUS) study, showed that the 
ARB olmesartan has a positive effect on coronary atheroscle-
rotic plaque.55 In this prospective, randomized multicenter 
trial, 247 patients with stable angina and native coronary 
artery disease underwent percutaneous coronary intervention 
for culprit lesions. Intravascular ultrasound (IVUS) examina-
tion was performed in the nonculprit lesions (stenosis ,50%) 
before and after 12–16 months of the randomized treatment 
regimens. Patients were randomly assigned to control (with-
out treatment with ACEIs or ARBs) or olmesartan 10–40 mg 
titrated to maximally tolerated dose by 8 weeks. Patients 
were also treated with a combination of β blockers, CCBs,  Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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diuretics, nitrates, glycemic control agents, and/or statins per 
physician’s guidance. Follow-up IVUS showed significantly 
decreased progression in total atheroma volume (0.6% vs 
5.4%, P , 0.05) and percent change in percent atheroma 
  volume (−0.7% vs 3.1%, P , 0.05) in the olmesartan com-
pared with control group. There were no significant differ-
ences in systolic and diastolic BP between groups either at 
baseline or 14-month follow-up.
Patient perspectives
Adherence rate is inversely related to the number of drugs 
given and occurrence of adverse effects.56 Adherence to antihy-
pertensive treatment is higher with single daily dose medication 
that reduces BP with low incidence of side effects. Compliance 
to the treatment is probably to increase if an antihypertensive 
agent combines these characteristics and, in addition, if patients 
are informed about extra protections of the medication.
Conclusion
BP reduction is the most effective way to reduce CV risk in 
patients with hypertension. Some antihypertensive agents have 
additional benefits that are independent of BP. Olmesartan 
effectively reduces BP and also has vasoprotective properties, 
including reductions in endothelial dysfunction and inflamma-
tion, prevention of microalbuminuria, and reversal of vascular 
remodeling. Large-scale, long-term   studies are needed to con-
firm that olmesartan has vasoprotective effects that are indepen-
dent of BP control and to determine whether these pleiotropic 
effects translate into improved CV disease outcomes.
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